drugset
drugset / Trial / NCT06230757

Psilocybin for Treatment-Resistant Depression

NCT06230757 ↗

Phase 2 Completed 20 enrolled University of Colorado, Denver
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.

Timeline

Start
2024-07-08
Primary completion
2026-05-08
Completion
2026-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

atypical depressive disorder major depressive disorder